{
  "pmcid": "PMC11430164",
  "pmid": "39346054",
  "title": "The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population",
  "overall_score": 0.0062245107073532905,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 8,
        "items": [
          {
            "variant": "CYP3A4*11",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*11",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*11 exhibited significantly higher intrinsic clearance compared to wild-type CYP3A4*1.",
              "Sentence": "CYP3A4*11 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*11",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type;",
                "CYP3A4*11 exhibited significantly higher intrinsic clearance compared to wild-type CYP3A4*1,",
                "CYP3A4*11, *18, and *33 show significantly higher catalytic activities compared to the wild-type."
              ]
            }
          },
          {
            "variant": "CYP3A4*18",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*18",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*18 displayed significantly higher intrinsic clearance than wild-type.",
              "Sentence": "CYP3A4*18 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*18",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type... CYP3A4*18 displayed significantly higher intrinsic clearance than wild-type.",
                "CYP3A4 gene polymorphism is an important factor in drug metabolism... We hope that these results will help to identify PMs, expand the existing database on CYP3A4 gene polymorphisms, facilitate the development of metabolic models, and provide valuable reference for predicting in vivo ticagrelor concentration.",
                "The results suggested that there is allele-specific activity towards ticagrelor in vitro."
              ]
            }
          },
          {
            "variant": "CYP3A4*33",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*33",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*33 showed significantly higher intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*33 is associated with increased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*33",
              "Metabolizer types": "extensive metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type;...",
                "CYP3A4*33 showed significantly higher intrinsic clearance compared to wild-type.",
                "...we evaluated the effect of CYP3A4*1G and 22 CYP3A4 variants, including seven new variants that specifically distributed in Chinese Han population, on ticagrelor metabolism..."
              ]
            }
          },
          {
            "variant": "CYP3A4*2",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*2",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*2 displayed significantly lower intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*2 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*2",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*2 exhibits a 74.48% decrease in intrinsic clearance for ticagrelor when compared to the wild-type.",
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type.",
                "This study aimed to evaluate the catalytic characteristics of 22 CYP3A4 alleles identified in the Chinese Han population on the metabolism of ticagrelor in vitro, focusing on the effect of CYP3A4 polymorphism on ticagrelor metabolism."
              ]
            }
          },
          {
            "variant": "CYP3A4*3",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*3",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*3 exhibited significantly lower intrinsic clearance than wild-type.",
              "Sentence": "CYP3A4*3 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*3",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type.",
                "CYP3A4*3 was first identified in Chinese subject from Shanghai... This study confirmed this point: the increase in Km is larger than that of Vmax, resulting in a 64.99% decrease in CLint for CYP3A4*3 compared with CYP3A4*1.",
                "In this study, we evaluated the effect of CYP3A4*1G and 22 CYP3A4 variants, including seven new variants that specifically distributed in Chinese Han population, on ticagrelor metabolism."
              ]
            }
          },
          {
            "variant": "CYP3A4*24",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*24",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*24 demonstrated severely reduced activity in ticagrelor metabolism.",
              "Sentence": "CYP3A4*24 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*24",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*24 (Q200H) involves an A \u2192T nucleotide substitution in exon 7, which causes a change from glutamine to histidine at position 220. In this study, CYP3A4*24 showed feeble catalytic activity towards ticagrelor, with only 1.48% relative clearance.",
                "CYP3A4*17 (F189S) and *24 (Q200H) exhibit severely reduced activity in the metabolism of ticagrelor, with over 90% decreased CLint compared to the wild-type."
              ]
            }
          },
          {
            "variant": "CYP3A4*30",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*30",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "not stated",
              "Notes": "CYP3A4*30 displayed weak or no activity.",
              "Sentence": "CYP3A4*30 is not associated with effective metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*30",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*30 displayed weak or no activity.",
                "CYP3A4*30 (R130STOP) could not be determined because of no detectable enzymatic activity toward ticagrelor.",
                "Our results provide some support for this prediction, indicating that CYP3A4*30 exhibits a markedly reduced Clint for ticagrelor, achieving only 4.72% of the activity observed in the wild-type."
              ]
            }
          },
          {
            "variant": "CYP3A4*17",
            "gene": "CYP3A4",
            "drug": "ticagrelor",
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*17",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4*17 showed significantly lower intrinsic clearance compared to wild-type.",
              "Sentence": "CYP3A4*17 is associated with decreased metabolism of ticagrelor in individuals of Chinese Han population.",
              "Alleles": "*17",
              "Metabolizer types": "poor metabolizer",
              "Comparison Allele(s) or Genotype(s)": "CYP3A4*1",
              "Comparison Metabolizer types": "normal metabolizer",
              "Specialty Population": "",
              "Population types": "in individuals of Chinese Han population",
              "Population Phenotypes or diseases": "",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": "",
              "Multiple phenotypes or diseases And/or": "",
              "Citations": [
                "CYP3A4*17 (F189S) and *24 (Q200H) exhibit severely reduced activity in the metabolism of ticagrelor, with over 90% decreased CLint compared to the wild-type.",
                "CYP3A4*17 exhibits a markedly reduced Clint for ticagrelor, achieving only 4.72% of the activity observed in the wild-type.",
                "The remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type."
              ]
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.03112255353676645,
      "total_samples": 19,
      "ground_truth_annotations": {
        "count": 19,
        "matched_count": 1,
        "unmatched_count": 18,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.5913285171985626,
            "annotation": {
              "Variant/Haplotypes": "CYP3A4*1",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP3A4*1",
                "prediction": "CYP3A4*1G",
                "score": 0.95,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP3A4",
                "prediction": "CYP3A4",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "ticagrelor",
                "prediction": "ticagrelor",
                "score": 1.0,
                "match_status": "match"
              },
              "PMID": {
                "ground_truth": 39346054,
                "prediction": 39346054,
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Metabolism/PK",
                "prediction": "metabolism/PK",
                "score": 1.0,
                "match_status": "match"
              },
              "Significance": {
                "ground_truth": "yes",
                "prediction": "yes",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
                "prediction": "*1G",
                "score": 0.8765703439712524,
                "match_status": "partial_match"
              },
              "Specialty Population": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Assay type": {
                "ground_truth": null,
                "prediction": "insect cells",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Metabolizer types": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              },
              "isPlural": {
                "ground_truth": "Is",
                "prediction": "Is",
                "score": 1.0,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Functional terms": {
                "ground_truth": "clearance of",
                "prediction": "clearance of",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene/gene product": {
                "ground_truth": null,
                "prediction": "CYP3A4",
                "score": 0.0,
                "match_status": "no_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": null,
                "prediction": "when assayed with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Multiple drugs And/or": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Cell type": {
                "ground_truth": null,
                "prediction": "in insect microsomes",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Comparison Metabolizer types": {
                "ground_truth": null,
                "prediction": "",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*2",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*3",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*4",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*5",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*9",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*14",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*15",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*16",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*17",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*19",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*24",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*28",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*29",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626580,
              "Variant/Haplotypes": "CYP3A4*31",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626580",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*1",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*11",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*18",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452626560,
              "Variant/Haplotypes": "CYP3A4*33",
              "Gene": "CYP3A4",
              "Drug(s)": "ticagrelor",
              "PMID": 39346054,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%-75.11% relative clearance) compared to that of wild-type",
              "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
              "Alleles": "*11 + *18 + *33",
              "Specialty Population": null,
              "Assay type": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Functional terms": "clearance of",
              "Gene/gene product": null,
              "When treated with/exposed to/when assayed with": null,
              "Multiple drugs And/or": null,
              "Cell type": null,
              "Comparison Allele(s) or Genotype(s)": "*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "39346054",
              "Variant Annotation ID_norm": "1452626560",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 6,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "22 CYP3A4 variants in Chinese Han population",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*11, higher intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 2.6473,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*18, increased intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 1.2249,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*33, higher intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 9.4029,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*30, weak or no activity",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": null,
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": null,
              "Study Cases": 22,
              "Study Controls": null,
              "Characteristics": "CYP3A4*24, low intrinsic clearance compared to wild-type",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.01",
              "Ratio Stat Type": "CLint",
              "Ratio Stat": 0.0148,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Chinese Han",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}